- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in lupin
Lupin, Glenmark, Dr Reddy's Recall Products In US
According to industry estimates, the US generic drug market was estimated to be around USD 115.2 billion in 2019
Read More
Lupin Recalls 4,113 Cartons Of Oral Contraceptive Medicine In US Market
The affected lot has been produced at the company's Pithampur-based manufacturing facility in Madhya Pradesh and distributed in the US by Baltimore-based Lupin Pharmaceuticals, Inc.
Read More
Lupin Announces Launch Of Its Diagnostics Business
The core facilities of the laboratory include all major diagnostics services, preventive health checkups, and a comprehensive range of tests.
Read More
Sun Pharma, Lupin Recall Products In US Market, Says USFDA
New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the company, has initiated the Class III nationwide (US) recall of the 10-count blister packs on October 12 this year.
Read More
Lupin To Acquire Australia-Based Southern Cross Pharma
This will significantly increase Lupin's value proposition and market share in the Australian market
Read More
Lupin Launches Generic Antifungal Product In US Market
Tavaborole Topical Solution is generic equivalent of Anacor Pharmaceuticals' Kerydin Topical Solution and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Read More
Lupin Arm Gets Supplemental New Drug Application Approval From USFDA For Solosec
Shares of Lupin Ltd closed at Rs 1,146.25 per scrip on BSE, down 0.26 per cent from its previous close.
Read More
Lupin Gets USFDA Nod To Market Sevelamer Hydrochloride Tablets
Sevelamer Hydrochloride Tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
Read More
Lupin Gets UK Marketing Authorisation For Generic Pressurised Metered Dose Inhaler
Shares of Lupin Ltd were trading at Rs 1,195.20 per scrip on BSE, down 2.85 per cent from its previous close.
Read More
Lupin Gets Warning Letter From USFDA For Somerset Facility
Lupin is committed to addressing the concerns raised by the USFDA and will work with the FDA and the New Jersey district to resolve these issues at the earliest
Read More
Lupin Launches Digital Asthma Educator Platform
The new platform is the latest initiative under Lupin's long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailments.
Read More
Lupin Launches Generic Inhalation Product In US Market
Shares of Lupin were trading 0.39 per cent up at Rs 1,237.20 apiece on the BSE.
Read More
Lupin To Enter Digital Healthcare Space In India
Shares of Lupin Ltd were trading 0.29 per cent lower at Rs 1,243.30 apiece on BSE.
Read More
Lupin Reports 18 % Increase In Q4 Net Profit At Rs 460 Cr; FY21 Profit At Rs 1,216 Cr
The drug firm noted that its capital expenditure for the fourth quarter stood at Rs 140 crore and for the full year (FY21) at Rs 628 crore.
Read More
Lupin, Sun Pharma, Jubilant Cadista Recall Drugs In US Market
The affected lot has been produced by Jubilant Generics at its Roorkee based plant in Uttarakhand and marketed in the US by Salisbury-based Jubilant Cadista Pharmaceuticals, Inc.
Read More